Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
40.50
-1.00 (-2.41%)
At close: Apr 20, 2026, 4:00 PM EDT
40.80
+0.30 (0.74%)
After-hours: Apr 20, 2026, 6:51 PM EDT
Harrow Employees
Harrow had 373 employees as of December 31, 2025. The number of employees decreased by 9 or -2.36% compared to the previous year.
Employees
373
Change (1Y)
-9
Growth (1Y)
-2.36%
Revenue / Employee
$730,035
Profits / Employee
-$13,777
Market Cap
1.51B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 373 | -9 | -2.36% | 373 | 0 |
| Dec 31, 2024 | 382 | 67 | 21.27% | 382 | 0 |
| Dec 31, 2023 | 315 | 98 | 45.16% | 315 | 0 |
| Dec 31, 2022 | 217 | 35 | 19.23% | 217 | 0 |
| Dec 31, 2021 | 182 | 57 | 45.60% | 182 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Evotec SE | 4,467 |
| Phibro Animal Health | 2,475 |
| Amphastar Pharmaceuticals | 1,976 |
| Alvotech | 1,279 |
| ANI Pharmaceuticals | 970 |
| Pacira BioSciences | 829 |
HROW News
- 4 days ago - Harrow Announces the Issuance of J-Code for IOPIDINE® 1% - GlobeNewsWire
- 6 days ago - LogiCare3PL Selected as Distribution Partner by Harrow - PRNewsWire
- 27 days ago - Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030 - GlobeNewsWire
- 27 days ago - Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth - GlobeNewsWire
- 4 weeks ago - Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting - GlobeNewsWire
- 6 weeks ago - These Analysts Revise Their Forecasts On Harrow Following Q4 Results - Benzinga
- 6 weeks ago - Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication - GlobeNewsWire